Results 71 to 80 of about 7,390 (165)

Anti-severe acute respiratory syndrome coronavirus-2 antibody responses following Pfizer-BioNTech vaccination in a patient with multiple sclerosis treated with ocrelizumab: a case report

Journal of International Medical Research, 2021
Patients with multiple sclerosis (MS) repeatedly receive therapies that cause B-lymphocyte depletion. This may lead to abnormal immune responses following coronavirus disease 2019 (COVID-19) vaccination, as has been suggested previously.
Hubert Mado, Katarzyna Kubicka-Bączyk, Monika Adamczyk-Sowa   +2 more
doaj   +1 more source

Advances in the treatment of systemic lupus erythematosus: Biologicals, small‐molecular agents, and cell‐depleting therapies coming to the clinic

Journal of Internal Medicine, Volume 300, Issue 4, Page 461-479, October 2026.
Abstract Systemic lupus erythematosus (SLE; lupus) remains a particular challenge for the practicing clinician on account of its chronic undulating and unpredictable course, its diverse manifestations, and—until recently—limited treatment options all associated with considerable downsides.
Ronald van Vollenhoven
wiley   +1 more source

Prediction of multiple sclerosis outcomes when switching to ocrelizumab

, 2021
Background: Increasingly, people with relapsing-remitting multiple sclerosis (RRMS) are switched to highly effective disease-modifying therapies (DMTs) such as ocrelizumab. Objective: To determine predictors of relapse and disability progression
Karabudak, R., Kuhle, J., Jokubaitis, V.G., Butler, E., Eichau, S., Girard, M., Prevost, J., Hodgkinson, S., Slee, M., Yeh, W., Barnett, M., Zhong, M., Kermode, A.G., Butzkueven, H., McCombe, P., Duquette, P., Alroughani, R., Van der Walt, A., Gresle, M., Macdonell, R., Stankovich, J., Grammond, P., Lechner-Scott, J., Skibina, O., Laureys, G., Kalincik, T., Taylor, B., van Pesch, V., Buzzard, K., Monif, M., Van Hijfte, L., Boz, C.   +31 more
core  

An exploratory analysis of the efficacy of ocrelizumab in patients with multiple sclerosis with increased disability

Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2020
Background Ocrelizumab, an anti-CD20 humanized monoclonal antibody, reduced disease progression in pivotal trials of patients with relapsing (OPERA I, OPERA II) and primary progressive (ORATORIO) multiple sclerosis (MS). These effects may be particularly
Jerry S Wolinsky, Natalie J Engmann, Jinglan Pei, Ashish Pradhan, Clyde Markowitz, Edward J Fox   +5 more
doaj   +1 more source

Paramagnetic Rim Lesions Are Associated With Trans‐Synaptic Degeneration of the Visual Pathway in Multiple Sclerosis

Annals of Clinical and Translational Neurology, Volume 13, Issue 9, Page 1831-1841, September 2026.
ABSTRACT Objectives Retrograde trans‐synaptic degeneration (rTSD) from posterior visual pathway lesions in multiple sclerosis (MS) is characterized by hemi‐macular ganglion cell‐inner plexiform layer (GCIPL) thinning and contralateral visual field loss.
Abdul Jaber Tayem, Angel Liu, Sargis Manukyan, Mustafa Subhi, Elaina Luskin, Bryan Quah, Sreekanth Madhusoodhanan Nair, Arzu C. Has Silemek, Gabriela Zabala, Yujie Cui, Laura Locke, Paula Barreras, Marwa Kaisey, Vinicius Calsavara, Daniel S. Reich, Nancy L. Sicotte, Pascal Sati, Omar Al‐Louzi   +17 more
wiley   +1 more source

Table_1_Case Report: Rapid Desensitization to Ocrelizumab for Multiple Sclerosis Is Effective and Safe.xlsx

, 2022
Monoclonal antibodies have become a mainstay of treatment for many inflammatory diseases and malignancies. Multiple sclerosis is a chronic inflammatory, demyelinating, and neurodegenerative disease of the central nervous system and a common cause of ...
Victor Hugo Rocha Marussi (10367964), Fernando Freua (5186750), Marcelo Vivolo Aun (8047541), Pedro Giavina-Bianchi (52912)   +3 more
core   +1 more source

Assessing Progression Independent of Relapse Activity in Multiple Sclerosis Using a Patient‐Reported Disability Measure and Self‐Administered Neuroperformance Outcomes

Annals of Neurology, Volume 100, Issue 3, Page 525-546, September 2026.
Objective The objective of this study was to investigate the ability of patient‐reported/administered outcomes to capture disability worsening and progression independent of relapse activity (PIRA) in multiple sclerosis (MS). Methods We included patients from the longitudinal multicenter MS PATHS cohort with ≥3 assessments and >6 months follow‐up. PIRA
Evy M. Reinders, Ariadna Masot‐Llima, Susana Otero‐Romero, René Carvajal, Álvaro Cobo‐Calvo, Pere Carbonell‐Mirabent, Jordina Beltran, Maria Jesús Arévalo, Helena Ariño, Georgina Arrambide, Cristina Auger, Luca Bollo, Joaquín Castilló, Manuel Comabella, Ingrid Galán, Alexis García‐Sarreón, Andrew Goodman, Carrie M. Hersh, Delon La Puma, Le H. Hua, Luciana Midaglia, Neus Mongay‐Ochoa, Ellen M. Mowry, Agustín Pappolla, Breogán Rodríguez‐Acevedo, Jordi Río, Paula Tagliani, Ángela Vidal‐Jordana, Andreu Vilaseca, Ana Zabalza, Deborah Pareto, Carlos Nos, Menno Schoonheim, Eva Strijbis, Jaume Sastre‐Garriga, Madalina Tivarus, Tjalf Ziemssen, Àlex Rovira, Xavier Montalban, Mar Tintoré, Carmen Tur   +40 more
wiley   +1 more source

Ocrelizumab-induced colitis acutely managed with ciclosporin

Ocrelizumab is an anti-CD20 monoclonal antibody widely used in the treatment of multiple sclerosis (MS). Although rare, ocrelizumab-induced colitis is a recognised and potentially severe condition that may require life-saving surgical intervention if ...
Stephanie Dimovski, Maddison Terlato, Jonathan P Segal   +2 more
core   +1 more source

Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis.

, 2017
An evolving understanding of the immunopathogenesis of multiple sclerosis suggests that depleting B cells could be useful for treatment. We studied ocrelizumab, a humanized monoclonal antibody that selectively depletes CD20-expressing B cells, in the ...
Montalban, Xavier;Hauser, Stephen L;Kappos, Ludwig;Arnold, Douglas L;Bar-Or, Amit;Comi, Giancarlo;de Seze, Jérôme;Giovannoni, Gavin;Hartung, Hans-Peter;Hemmer, Bernhard;Lublin, Fred;Rammohan, Kottil W;Selmaj, Krzysztof;Traboulsee, Anthony;Sauter, Annette;Masterman, Donna;Fontoura, Paulo;Belachew, Shibeshih;Garren, Hideki;Mairon, Nicole;Chin, Peter;Wolinsky, Jerry S
core   +1 more source

Exploring Healthcare Continuity in Pediatric‐Onset Multiple Sclerosis in the United States

Annals of the Child Neurology Society, Volume 4, Issue 3, Page 177-187, September 2026.
ABSTRACT Objective Little is known about shifting from pediatric to adult‐focused multiple sclerosis (MS) care. This study aims to explore transition of care and follow‐up in the US pediatric‐onset MS (POMS) population. Methods Surveys were distributed to 10 sites in the US Network of Pediatric MS Centers (US NPMSC) about transition‐of‐care practices ...
Aaron W. Abrams, Michael Waltz, Jonathan Race, T. Charles Casper, Claudia Gambrah‐Lyles, Kimberly O'Neill, Akash Virupakshaiah, Kristen S. Fisher, Melissa A. Wright, Kelsey E. Poisson, Eva‐Chava M. Bernfeld, Gregory Aaen, Leslie A. Benson, Tanuja Chitnis, Carla Francisco, Grace Y. Gombolay, Mark P. Gorman, Jennifer S. Graves, Lauren Krupp, Timothy E. Lotze, Soe Mar, Jayne Ness, Mary Rensel, Moses Rodriguez, Teri Schreiner, Nikita Shukla, Jan‐Mendelt Tillema, Bianca Weinstock‐Guttman, Yolanda Wheeler, Emmanuelle Waubant, John Rose, US Network of Pediatric MS Centers   +31 more
wiley   +1 more source